Investment Thesis
Nuwellis is a cash-burning medical device company with declining revenue, operating losses consuming 192% of revenue, and only 8 months of cash runway at current burn rates. Despite healthy 70% gross margins indicating viable product economics, the company faces existential risk without near-term profitability achievement or significant capital infusion.
Strengths
- Strong gross margin of 70.1% indicates underlying product viability and pricing power
- Moderate leverage (0.74x Debt/Equity) provides some financial flexibility
- Asset-light model with minimal capex requirements ($30K) reduces capital intensity
Risks
- Negative operating cash flow of -$3.1M with only $2.1M cash = ~8 months runway before insolvency
- Revenue declining 5.4% YoY while operating losses exceed revenue by 2x, indicating failed commercialization
- Operating margin of -190% with -$4.6M operating loss on $2.4M revenue shows inability to control costs or scale efficiently
- Negative ROE (-170.7%) and ROA (-65.2%) demonstrate severe value destruction
- Interest coverage of -9.1x reflects inability to service debt from operations
Key Metrics to Watch
- Quarterly revenue trend and return to growth trajectory
- Operating expense reduction and path to positive operating income
- Cash burn rate and months of cash runway remaining
- Operating cash flow inflection to positive
- Capital raise announcements or partnership developments indicating survival strategy
Financial Metrics
Revenue
2.4M
Net Income
-4.5M
EPS (Diluted)
$-2.19
Free Cash Flow
-3.1M
Total Assets
7.0M
Cash
2.1M
Profitability Ratios
Gross Margin
70.1%
Operating Margin
-190.1%
Net Margin
-189.0%
ROE
-170.7%
ROA
-65.2%
FCF Margin
-130.8%
Balance Sheet & Liquidity
Current Ratio
1.56x
Quick Ratio
1.09x
Debt/Equity
0.74x
Debt/Assets
61.7%
Interest Coverage
-9.06x
Long-term Debt
2.0M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-16T07:48:16.606294 |
Data as of: 2026-03-31 |
Powered by Claude AI